Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 9/2019

01.06.2019 | AdisInsight Report

Siponimod: First Global Approval

verfasst von: Zaina T. Al-Salama

Erschienen in: Drugs | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Siponimod (Mayzent®) is an oral selective sphingosine 1-phosphate receptor subtypes 1 and 5 (S1PR1,5) modulator being developed by Novartis Pharmaceuticals for the treatment of multiple sclerosis (MS) and intracerebral haemorrhage. In March 2019, siponimod received its first global approval in the USA, for the treatment of adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Siponimod is under regulatory review in the EU and Japan for secondary progressive MS. This article summarizes the milestone in the development of siponimod leading to this first global approval for MS in the USA.
Literatur
1.
Baldassari LE, Fox RJ. Therapeutic advances and challenges in the treatment of progressive multiple sclerosis. Drugs. 2018;78(15):1549–66.CrossRefPubMed
2.
De Angelis F, Plantone D, Chataway J. Pharmacotherapy in secondary progressive multiple sclerosis: an overview. CNS Drugs. 2018;32(6):499–526.CrossRefPubMed
3.
4.
Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics. 2017;14(4):859–73.CrossRefPubMedPubMedCentral
5.
O’Sullivan C, Schubart A, Mir AK, et al. The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflamm. 2016;13:31.CrossRef
6.
Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–47.CrossRefPubMedPubMedCentral
7.
Lewis ND, Haxhinasto SA, Anderson SM, et al. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J Immunol. 2013;190(7):3533–40.CrossRefPubMed
8.
Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflamm. 2016;13(1):207.CrossRef
9.
Mao-Draayer Y, Wu Q, Wang Q, et al. Basic immunological profile changes of SPMS patients treated with BAF312 [abstract no. P1.384]. Neurology. 2017;88(16 Suppl.).
10.
Bar-Or A, Derfuss T, Vermersch P, et al. Longitudinal changes in lymphocyte subsets of siponimod treated patients with SPMS [abstract no. P1238]. Mult Scler J. 2017;23(Suppl. 3):660.
11.
Kuhle J, Kropshofer H, Barro C, et al. Siponimod reduces neurofilament light chain blood levels in secondary progressive multiple sclerosis patients [abstract no. S8.006]. Neurology. 2018;90(15 Suppl.).
12.
Biswal S, Polus F, Pal P, et al. Pharmacokinetic and pharmacodynamic interaction of siponimod (BAF312) and propranolol in healthy subjects. Int J Clin Pharmacol Ther. 2015;53(10):855–65.CrossRefPubMed
13.
Shakeri-Nejad K, Aslanis V, Veldandi UK, et al. Effects of therapeutic and supratherapeutic doses of siponimod (BAF312) on cardiac repolarization in healthy subjects. Clin Ther. 2015;37(11):2489–2505.e2.CrossRefPubMed
14.
Glaenzel U, Jin Y, Nufer R, et al. Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018;46(7):1001–13.CrossRefPubMed
15.
Gardin A, Shakeri-Nejad K, Gray C, et al. Absolute bioavailability of single, oral dose of siponimod in healthy subjects [abstract no. P3.402]. Neurology. 2018;90(15 Suppl.).
16.
Gardin A, Ufer M, Legangneux E, et al. Effect of fluconazole coadministration and CYP2C9 genetic polymorphism on siponimod pharmacokinetics in healthy subjects. Clin Pharmacokinet. 2019;58(3):349–61.CrossRefPubMed
17.
Gardin A, Gray C, Neelakantham S, et al. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. Eur J Clin Pharmacol. 2018;74(12):1593–604.CrossRefPubMed
18.
Huth F, Gardin A, Umehara K-I, et al. Prediction of the impact of CYP2C9 genotypes on the drug-drug interaction potential of siponimod with PBPK modeling:a comprehensive approach for drug label recommendations. Clin Pharmacol Ther (in press).
19.
Gardin A, Dodman A, Kalluri S, et al. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: a single-dose, open-label, parallel-group study. Int J Clin Pharmacol Ther. 2017;55(1):54–65.CrossRefPubMed
20.
Shakeri-Nejad K, Aslanis V, Veldandi UK, et al. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study. Int J Clin Pharmacol Ther. 2017;55(1):41–53.CrossRefPubMed
21.
Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–73.CrossRefPubMed
22.
Cree B, Fox R, Giovannoni G, et al. Siponimod affects disability progression in SPMS patients independent of relapse activity: results from the phase III EXPAND study [abstract no. O330]. Eur J Neurol. 2018;25(Suppl. 2):70–1.
23.
Cree B, Fox R, Giovannoni G, et al. Uncoupling the impact on relapses and disability progression: siponimod in relapsing and non-relapsing patients with secondary progressive multiple sclerosis in the phase III EXPAND study [abstract no. S8.005]. Neurology. 2018;90(15 Suppl.).
24.
Benedict RHB, Cree B, Tomic D, et al. Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: results from phase 3 EXPAND study [abstract no. S44.004]. Neurology. 2018;90(15 Suppl.).
25.
Benedict RH, Cree B, Tomic D, et al. Siponimod improves cognitive processing speed in patients with SPMS: results from Phase 3 EXPAND Study [abstract no. EPR2103]. Eur J Neurol. 2018;25(Suppl. 2):432.
26.
Benedict R, Fox R, Tomic D, et al. Effect of siponimod on cognition in patients with secondary progressive multiple sclerosis (SPMS): phase 3 EXPAND study subgroup analysis [abstract no. P3.2-051]. Neurology. 2019;92(15 Suppl).
27.
Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67.CrossRefPubMed
28.
Kappos L, Li DK, Stuve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73(9):1089–98.CrossRefPubMed
29.
Kappos L, Vermersch P, Fox R, et al. Longer-term safety with siponimod treatment in multiple sclerosis: pooled analysis of data from the BOLD and EXPAND trials and their extensions [abstract no. P911]. Mult Scler J. 2018;24(Suppl. 2):491–2.
30.
Metadaten
Titel
Siponimod: First Global Approval
verfasst von
Zaina T. Al-Salama
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 9/2019
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-019-01140-x

Weitere Artikel der Ausgabe 9/2019

Drugs 9/2019 Zur Ausgabe

Adis Drug Evaluation

Tiotropium/Olodaterol: A Review in COPD

Leading Article

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

AdisInsight Report

Sotagliflozin: First Global Approval

Leading Article

Nutritional Psychiatry: From Concept to the Clinic

Review Article

Medical Management of Cushing’s Syndrome: Current and Emerging Treatments

Review Article

Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain